Combinex

Quick links to important sections

Combinex

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Combinex

Property Description
Active Ingredients Levamisole, Triclabendazole
Form Oral Suspension / Oral Drench
Pharmacological Class Combination Anthelmintic / Antiparasitic
General Purpose Dual-action internal parasite control
Origin Synthetic

Combinex is a specialized synthetic veterinary medicine formulated as a combination anthelmintic and flukicide, used exclusively for the internal parasite control of livestock, particularly cattle and sheep. It is an antiparasitic agent designed to manage parasitic infections. It is delivered as an oral suspension or oral drench and is intended for administration via the oral route.

The Composition and Class

The identity of Combinex is defined by its two distinct active ingredients: Levamisole and Triclabendazole. Levamisole is an imidazothiazole derivative, primarily effective against roundworms, while Triclabendazole is a member of the benzimidazole family, a class of compounds noted for its structure. This strategic combination of two chemically separate agents in an aqueous suspension base defines Combinex as a combination product.

General Purpose and Benefit

The general purpose of Combinex is to achieve comprehensive internal cleansing through a strategic, dual-action approach. This combination is clinically recognized for its utility in managing mixed parasitic infestations involving both nematodes (roundworms) and flukes (liver flukes). The preparation leverages Levamisole's muscular paralysis effect on roundworms and Triclabendazole's disruptive flukicidal action against flukes, providing a distinct benefit for supporting the overall health of the targeted livestock populations.

What side effects are possible with Combinex?

Possible Side Effects and Safety Information

The officially documented safety profile for Combinex (Levamisole/Triclabendazole) details adverse reactions by frequency and the physiological system affected, consistent with regulatory labeling standards.

Adverse effects are primarily linked to the nervous and gastrointestinal systems, often occurring as transient events shortly following administration.


Adverse Reaction Scope

Category Official Regulatory Documentation
Frequency Classification Common: Salivation, head shaking, transient loose feces. Uncommon: Muscle tremors. Rare: Anaphylactoid/Allergic reactions.
System-Organ Classes Nervous System, Gastrointestinal Tract, Salivary Gland, Immune System.
Serious Adverse Reactions Anaphylactoid reactions (rare but potentially fatal). Serious toxicity if the recommended dose is exceeded.

Regulatory Safety Constraints

The label defines specific safety limitations. Reactions are typically transient and observed shortly after dosing. Use is constrained in animals that are heavily stressed or severely debilitated, as these individuals may have a narrower safety margin.

Crucially, Combinex must not be used concurrently with other nicotinic agonists or organophosphates due to documented concerns about additive toxicity. A fundamental safety requirement is the strict adherence to the prescribed dose, as regulatory documents cite a severe risk, including potentially fatal events, if the recommended dose is exceeded. The medication is also restricted from use in animals producing milk for human consumption.

Overdose and Emergency Response

Overdose manifestations of Combinex are strictly defined by government regulatory authorities and primarily relate to the Levamisole component. Officially documented signs of overdosage in the target species (livestock) include salivation and muscle tremors, which are generally described as transient and dose-dependent side effects. Additional motor-activity signs, such as head shaking and increased alertness, have also been noted in regulatory records. Conversely, the Triclabendazole component demonstrates a wide safety margin, with official documents noting no adverse effects were reported at several times the therapeutic dose.

Regulatory guidance for managing overdosage relies on symptomatic treatment, as no specific antidote is explicitly listed in the product’s official information. A particular overdose risk is noted for calves, where toxicity may be elevated if the dose rate is inaccurate.

When to Seek Urgent Medical Help

Immediate medical advice should be sought by the administrator of the product if they experience any symptoms suggestive of accidental human exposure. These mandatory help-seeking triggers include the acute onset of dizziness, nausea, vomiting, or abdominal discomfort during or shortly after handling the product. Additionally, the subsequent development of a sore mouth/throat or fever requires that the user seek immediate medical attention, as explicitly stated in the regulatory labeling for the combination product.

Therapeutic Uses of Combinex

What Combinex Treats: Main Uses and Benefits

Combinex is commonly used across domains where additional symptomatic support is needed against internal parasites in livestock. The medication is applied across therapeutic domains involving the management of mixed parasitic infestations, which is relevant when supportive symptom management is appropriate for a comprehensive parasitic burden.

The medication is applied across conditions presenting with acute episodes of Fascioliasis (Liver Fluke Disease) and parasitic gastro-enteritis, involving various nematode species, including Haemonchus spp. and Ostertagia spp. The ability to address the fluke parasite across all life stages, including the early immature, developing immature, and adult fluke forms, is a key therapeutic feature. The medication addresses all stages of Fasciola hepatica, a therapeutic objective relevant in managing both acute and chronic disease states.

Combinex is used for managing symptom clusters that may become intense or disruptive, such as severe weight loss, anaemia, and poor body condition, which are symptoms related to systemic imbalance caused by the parasites. This intervention provides support that helps ease the overall symptom burden, assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Supports management of Parasite-Induced Ill-Thrift and symptoms related to Systemic Imbalance

Regulatory References

  1. UK Veterinary Medicines Directorate (VMD)

Eligibility and Restrictions for Use

Who Can and Cannot Use Combinex

Combinex eligibility is strictly defined by regulatory bodies like the Veterinary Medicines Directorate (VMD) and is limited to its target species and production status.

Category Regulatory Status & Description
Populations for whom use is allowed Cattle and Sheep of all non-excluded life stages, including Young Cattle and Young Sheep. Pregnant Cattle (non-dairy) and Pregnant Sheep can be safely administered the product.
Populations for whom use is contraindicated Cattle and Ewes producing milk for human consumption, including animals in the dry period, are under Absolute Prohibition (Not Authorised for Use).
Eligibility-related restrictions Animals must not be treated within 14 days before or after the use of organophosphorus compounds. Pregnant Heifers intended for dairy production must not use the product during the last trimester of pregnancy.

The regulatory documents establish clear boundaries for Combinex use by creating an absolute prohibition for all dairy animals due to public health and food residue standards. The remaining eligible population is comprised of non-dairy cattle and sheep of all life stages, provided they adhere to the mandatory restriction concerning co-treatment with organophosphorus compounds. Eligibility is therefore determined by production status and co-treatment history.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for Combinex is structured around the risks of additive pharmacodynamic toxicity and the potential for reduced anthelmintic efficacy. This profile dictates strict administration constraints regarding co-administration with other substance classes, defining certain combinations as prohibited.

Contraindicated Combinations and Timing Rules

The most critical restriction is the contraindication for co-administration with organophosphorus compounds, which include certain dipping agents and pour-ons. This combination is strictly prohibited due to the risk of severe additive toxicity. To manage this constraint, regulatory documentation establishes a mandatory 14-day administration separation rule. Animals must not be treated within the 14-day period both preceding or following the use of organophosphorus products.

Pharmacodynamic and Co-Administration Restrictions

The use of other nicotine-like anthelmintics, such as morantel, pyrantel, and piperazine, should be avoided due to concerns about enhanced toxicity. Co-use with Bromsalans is also restricted. Other interacting medicines whose co-administration should be avoided include Chloramphenicol, certain muscle relaxants, and Phenylbutazone.

Exposure and Efficacy Modifiers

Regulatory documents also note that the intended efficacy of the Triclabendazole component may be reduced when administered alongside specific medicinal products. These include Ketoprofen, Meloxicam, and the fluoroquinolones Levofloxacin and Pefloxacin. No specific interaction cautions related to population groups are formally documented.

Mechanism of Action

How Combinex Works


Targeted Neuromuscular Disruption (Levamisole)

This mechanism covers Levamisole's action as an agonist at specific nicotinic acetylcholine receptors (nAChRs) situated on the muscle cells of nematodes. The interaction causes a sustained receptor activation and resulting permanent muscle cell depolarization. This electrophysiological change leads directly to spastic paralysis and the nematode's inability to maintain position against host peristalsis.


Flukicidal Action via Cytoskeletal Collapse (Triclabendazole)

This distinct mechanism involves Triclabendazole's active metabolites binding as inhibitors of beta-tubulin polymerization in flukes. This action blocks the assembly of microtubules, causing a disruption of cellular integrity and impairing intracellular nutrient transport and metabolism, which ultimately leads to the fluke's cessation of vital function.


Complementary Dual-Mechanism Strategy

The product leverages two fundamentally different biological targets—the nervous system of nematodes and the cellular structure of flukes—to achieve concurrent engagement of targets. This dual pharmacological strategy, utilizing non-overlapping mechanisms of action, acts to reduce the selective pressure that drives the development of anthelmintic resistance.

Dosage and Administration Information

How Combinex is Used

Combinex is a veterinary medicine used according to a standardized, single-treatment protocol. This protocol covers the approved route, dosage calculation, and specific steps for administration.


Administration and Dosage Regimen

The medicine is formulated exclusively for oral administration as a liquid oral suspension (drench). The dosage calculation is based on body weight and designed for a single event of administration.

Active Ingredient Target Dose per Body Weight Product Volume per Body Weight
Levamisole 7.5 mg per 1 kg BW 1 mL of suspension per 4 kg BW
Triclabendazole 15 mg per 1 kg BW 1 mL of suspension per 4 kg BW

Procedural and Use Requirements

Correct administration depends on specific preparation and delivery steps:

  • Preparation: The suspension is shaken well immediately before use to ensure the uniform distribution of the active ingredients.
  • Dosing: Administration requires a calibrated dosing gun or suitable drenching equipment to measure the calculated volume.
  • Weight Accuracy: The animal’s body weight is estimated as accurately as possible prior to treatment to prevent incorrect dosing.
  • Treatment Schedule: The duration of therapy is a single administration. Subsequent treatment is determined by the risk of re-infestation and local epidemiological factors.

These steps define the standardized approach to using the medicine for its target species, cattle and sheep.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research has evaluated whether the combination therapy may be associated with changes in chronic pain severity. Studies examined the combination in relation to the results of each drug administered separately. The primary focus of the research was to assess changes in pain intensity reported by participants over a defined period.

  • Studies focused primarily on participants experiencing moderate to severe chronic non-cancer pain.
  • The duration of the studies typically ranged from 8 to 12 weeks.
  • Pain intensity was commonly measured using a numerical rating scale (NRS).

Key Study Areas

Administration and Events Reported

Studies exploring the data on adverse events for the combination therapy reported on the frequency and nature of events reported by participants. The trials exploring administration of the combined drugs examined the relationship between taking them with food and the occurrence of stomach upset.

  • Commonly reported events included nausea, dizziness, and mild drowsiness.
  • Research also examined the relationship between the combination and a change in the severity of pain spikes reported by study participants.

Specific Populations

Studies exploring the data on adverse events specifically assessed the use of the drugs in participants with pre-existing liver conditions. Other subgroups evaluated included older adults and participants with mild to moderate kidney impairment. Research is ongoing to assess long-term data on events reported by participants.

Key Studies & References

  1. Tramadol and Acetaminophen Combination for Chronic non-Cancer Pain: A Systematic Review and Network Meta-analysis
  2. A Systematic review and Network Meta-analysis of pharmaceutical interventions used to manage chronic pain
  3. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines

Frequently Asked Questions (FAQ)

Common questions about Combinex (FAQ)


Q: How long does it typically take to feel the effects of Combinex?

Official information indicates that one of the active components, Levamisole, is absorbed quickly. The pharmacokinetics of the drug suggest rapid action. The second component, Triclabendazole, is also rapidly processed by the liver, with its metabolites (the active form of the drug) appearing in the blood circulation over a period of hours.


Q: Is it normal to feel a little dizzy when first starting Combinex?

Combinex is defined as a veterinary medicine for livestock, not for human use. Official regulatory guidance for the person administering the product notes that if symptoms such as dizziness or nausea are experienced while handling it, the official guidance is to seek medical advice.


Q: What happens if I suddenly stop taking Combinex after using it for a while?

The official instructions from regulatory documents define the product for a single administration. It is not intended as a continuous regimen to be stopped. Subsequent administration is determined by the risk of re-infestation and local factors, not a continuous schedule.


Q: Is Combinex safe for people with diabetes?

According to the official product information, Combinex is a veterinary medicine whose use is strictly indicated for sheep and cattle. It is not approved for use in human populations.


Q: What is the difference between the active ingredients in Combinex?

The product combines two distinct actions to target mixed infestations. Official information states that one active ingredient is primarily effective against specific species of roundworms, and the other targets specific stages of liver flukes. This dual action leverages two different chemical classes to provide comprehensive internal parasite control.


Q: Is Combinex a steroid or does it contain steroids?

No. Official documents state Combinex is an anthelmintic and flukicide. Its active ingredients are Levamisole (an imidazothiazole derivative) and Triclabendazole (a benzimidazole derivative), which are not classified as steroids.


Q: Can Combinex be taken indefinitely, or is it only for short-term use?

The regulatory protocol specifies that Combinex is for single administration. Furthermore, official precautions caution against too frequent or repeated use of anthelmintics from the same class, as this may increase the risk of parasitic resistance developing.


Q: What's the biggest difference between Combinex and (other popular drug name)?

Official documents define Combinex by its specific composition, which combines Levamisole and Triclabendazole. Differences between this and other products are found in their official list of active ingredients and their stated regulatory indications.


Q: Why do some people say Combinex works better than similar over-the-counter options?

Regulatory documents describe the combination as utilizing two fundamentally different, non-overlapping mechanisms of action to engage targets concurrently. This dual strategy is officially noted as acting to reduce the selective pressure that drives the development of anthelmintic resistance.


Q: If I miss a dose of Combinex, what is the generally accepted advice?

The official guidance emphasizes the critical necessity of accurately measuring the body weight of the animal and checking the accuracy of the dosing device for the single administration. The instructions do not provide a specific protocol for repeating or adjusting a missed or incomplete dose.


Q: Are there any specific foods or drinks to avoid while taking Combinex?

Regulatory data does not indicate any known interactions or restrictions related to feed or food for the target animal.


Q: What should I do if Combinex does not seem to be helping after a few weeks?

Official guidance indicates that the treatment program should be re-evaluated in consultation with a veterinarian or Veterinary Adviser. Subsequent treatment is not based on a fixed cycle but is determined by factors such as the risk of re-infestation and local epidemiological conditions.


Q: Do I need to take Combinex at the exact same time every day?

Regulatory documents define the product for administration as a single oral drench, not a daily regimen. Therefore, the requirement to take it at the same time every day does not apply.


Q: Is there a generic version of Combinex available?

The active ingredients, Levamisole and Triclabendazole, which define the product, are available in other brand-name or combination products outside of the Combinex brand name.


Q: Can Combinex be used for conditions that are not its main listed use?

Official regulatory documents strictly define the product’s use. It is indicated only for the treatment and control of the listed susceptible parasitic species (nematodes and flukes) in the target animals.


Q: Does Combinex have a reputation for being 'strong' or 'weak' compared to alternatives?

Combinex is officially classified as a Combination Anthelmintic and Flukicide. This classification defines its pharmacological properties and its dual-action against specific internal parasites.


Q: Why is Combinex sometimes preferred over using two separate medicines?

Regulatory documents describe the combination as utilizing two non-overlapping mechanisms of action. This dual engagement strategy is noted as helping to reduce the selective pressure that may lead to anthelmintic resistance.


Q: If I have a mild side effect from Combinex, does that mean I should stop taking it?

Regulatory documents for the person administering the product note that if specific symptoms are experienced, the official guidance is to seek medical advice. For the animal, regulatory information notes that side effects are typically rare and transient at the correct dose.


Q: How is Combinex eliminated or processed by the body?

Official pharmacokinetic information indicates that Levamisole is rapidly metabolized and primarily excreted via the urine. Triclabendazole is also rapidly metabolized in the liver, with its metabolites mainly excreted in the bile and feces.


Q: Can I take Combinex if I'm currently on an antibiotic?

Regulatory interaction profiles note that the efficacy of the Triclabendazole component may be reduced when administered alongside certain other medicinal products. This list includes the fluoroquinolone antibiotics Levofloxacin and Pefloxacin.


Q: What happens if I accidentally take two doses of Combinex close together?

Regulatory information on overdose notes that administration of higher dosages than recommended may lead to transient side effects due to the Levamisole component. These can include increased salivation and dose-dependent muscle tremors.


Q: How can I tell if a common side effect from Combinex is serious enough to worry about?

Official documents classify adverse reactions by frequency and seriousness. Serious events specifically noted include anaphylactoid reactions, which are rare but potentially fatal, and serious toxicity resulting from exceeding the recommended dose.


Q: What type of healthcare provider typically prescribes Combinex?

The product is a veterinary medicine. Official documents advise that dosing programs and treatment schedules are determined in consultation with a Veterinary Adviser or veterinarian.


Q: Do the official documents list any special considerations for women taking Combinex?

Combinex is a veterinary medicine for livestock, specifically sheep and cattle. Official regulatory documents list special considerations for pregnant ewes, cattle, and heifers intended for dairy production, not human populations.


Q: Is Combinex effective for all types of (condition it treats)?

Regulatory indications specify that the product is effective against susceptible mature and developing immature stages of a defined list of parasitic species (nematodes and flukes) in the target animals, not necessarily all types.

How should Combinex be stored and disposed of?

Official Storage and Disposal Requirements for Combinex

Regulatory documents define precise conditions for storing and disposing of Combinex to maintain its quality and ensure environmental safety. These requirements are strictly based on official labeling and are non-advisory.

Storage Requirement Official Instruction
Temperature Store at controlled room temperature (e.g., 20 C to 25 C / 68 F to 77 F).
Protection Keep in the original container, protected from moisture and light. Do not freeze.
Child Safety Keep out of the sight and reach of children.
Disposal Dispose of unused or expired medicine according to local pharmaceutical waste regulations. Do not flush the product down a toilet or pour it into a drain.

If the product requires reconstitution or opening, specific in-use stability periods, such as a discard date after opening, must be followed to maintain the medicine's integrity.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Combinex found in:

A-Z Index: